{"url_path":"/sec/drmaw/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-022719-index.html","accession_number":"0001493152-26-022719","cik":"0001853816","ticker":"DRMA","issuer_name":"Dermata Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1853816/0001493152-26-022719-index.html","primary_entity_key":"0001853816","primary_entity_name":"Dermata Therapeutics, Inc."},"word_count":212,"has_tables":true,"body_markdown":"** **\n\n**ITEM\n6: EXHIBITS**\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n16.1\n \n[Letter to Securities and Exchange Commission from Baker Tilly US, LLP, dated February 3, 2026 (incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K filed on February 3, 2026).](https://www.sec.gov/Archives/edgar/data/1853816/000149315226004905/ex16-1.htm)\n\n \n \n \n\n31.1*\n \n[Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).](ex31-1.htm)\n\n \n \n \n\n31.2*\n \n[Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).](ex31-2.htm)\n\n \n \n \n\n32.1**\n \n[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).](ex32-1.htm)\n\n \n \n \n\n101.INS*\n \nXBRL\nInstance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within\nthe Inline XBRL document\n\n101.SCH*\n \nInline\nXBRL Taxonomy Extension Schema Document\n\n101.CAL*\n \nInline\nXBRL Taxonomy Extension Calculation Linkbase Document\n\n \n\n*\nFiled herewith.\n\n**\nFurnished, not filed.\n\n \n\n33\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned, thereunto duly authorized.\n\n \n\n \nDermata\nTherapeutics, Inc.\n\n \n \n \n\nDate:\nMay 13, 2026\nBy:\n*/s/\nGerald T. Proehl*\n\n \n \nGerald\nT. Proehl\n\n \n \nPresident\nand Chief Executive Officer\n\n \n \n(Principal\nExecutive Officer)\n\n \n \n \n\n \nBy:\n*/s/\nKyri K. Van Hoose*\n\n \n \nKyri\nK. Van Hoose\n\n \n \nSenior\nVice President, Chief Financial Officer\n\n \n \n(Principal\nFinancial Officer and Principal Accounting Officer)\n\n \n\n34"}